Novo Nordisk to phase out key drug, insulin cos spot big biz opportunity

Novo Nordisk is set to discontinue some forms of its Mixtard insulin, including pen and cartridge versions, in India, coinciding with the anticipated launch of its weight-loss drug Wegovy. This move has prompted other major insulin manufacturers like Lupin, Eris, and Eli Lilly to increase their production capabilities to address the potential supply gap.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/P92tRq6
via IFTTT